OpenEvidence as AI-native Regeneron

This points to a business that could graduate from selling clinician attention to owning drug assets. OpenEvidence already has physician distribution, medical content, and its own stack of medical models, and it has now said it is developing rare cancer therapies. The Regeneron comparison matters because Regeneron turned a proprietary discovery engine into approved drugs and long lived economics, not just software revenue.1 2 3 4

• Regeneron is the template because it is not just a biotech with one hit drug. It reported $14.3B in 2025 revenue, nearly 50 pipeline candidates, and 16 approved or authorized treatments developed in house, showing what it looks like when a discovery platform repeatedly turns science into products.4 5
• OpenEvidence has built the front end data loop that a drug company normally does not have. More than 65% of U.S. physicians use it monthly, more than 50% use it daily, it handles about 20 million clinical consultations a month, and it has expanded from search into notes, coding, prescribing, and EHR linked workflows.2 3
• The strategic jump is economic, not cosmetic. Ads can fund free usage, but proprietary therapies create a second model where OpenEvidence can generate a candidate, advance it, and keep the downstream value through licensing or commercialization. That is why the upside is described as asymmetric relative to an ad supported clinician tool.1 2 3

The next phase is a split screen company, with one side acting like a free clinical operating system for doctors and the other side using that data, workflow access, and model specialization to feed a therapeutics engine. If that works, OpenEvidence starts to look less like UpToDate with ads and more like a software to biotech compounder.1 2 3 4